CDK10: A Potential Drug Target and Biomarker for Cancer Treatment

Target Name: CDK10

NCBI ID: G8558

CDK10

CDK10: A Potential Drug Target and Biomarker for Cancer Treatment

Introduction

The Cyclin dependent kinase (CDK) family is an important cell cycle regulatory protein that plays a key role in the occurrence, growth and progression of various cancers. CDK10 is a representative member of the CDK family and is involved in regulating spindle formation and mitosis processes in the cell cycle. CDK10 is up-regulated in a variety of cancers, and its expression level is closely related to disease prognosis and treatment response. Therefore, it is of high value to study the application prospects of CDK10 in cancer treatment.

The role and structure of CDK10

CDK10 is a 22kDa protein that contains an artificially designed leucine residue (Lys20) at its N-terminus, which can be used as a target for proteins and drugs. The C-terminus of CDK10 contains a benzimidazole ring structure and has a single-chain structure. CDK10 plays an important role in the cell cycle, including processes such as spindle formation, chromosome segregation, and mitosis progression.

The relationship between CDK10 and cancer

Studies have shown that CDK10 expression is up-regulated in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc. Moreover, the expression level of CDK10 is closely related to disease prognosis and treatment response. For example, patients with higher levels of CDK10 expression tend to have worse survival rates, and patients who receive chemotherapy tend to have elevated CDK10 expression levels.

In addition, CDK10 is also related to the apoptosis and proliferation of tumor cells. Studies have shown that the expression level of CDK10 is related to the apoptosis of tumor cells, and the expression level of CDK10 is also related to the proliferation of tumor cells. Therefore, studying the role of CDK10 in tumor treatment is of great significance for improving the effect of tumor treatment.

Pharmacological significance of CDK10

1. As a drug target

As a protein target, CDK10 has good pharmacological significance. By targeting CDK10, the spindle formation of tumor cells can be inhibited, thereby inhibiting the mitosis of tumor cells and achieving the purpose of treating tumors.

Currently, drugs targeting CDK10 are in clinical trials. For example, CDK10 inhibitors such as Ipilimumab and Nivolumab have achieved significant efficacy in the treatment of various cancers. These drugs specifically bind to CDK10 and inhibit its function, thereby inhibiting spindle formation and mitosis of tumor cells to achieve the purpose of treating tumors.

2. As a tumor biomarker

The role of CDK10 in tumor treatment is also reflected in its application value as a tumor biomarker. Studies have shown that the expression level of CDK10 can be used as an important indicator of prognosis and treatment response of tumor patients. For example, patients with higher levels of CDK10 expression tend to have worse survival rates, and patients who receive chemotherapy tend to have elevated CDK10 expression levels.

In addition, CDK10 can also be used as an important indicator of disease progression in tumor patients. Studies have shown that CDK10 expression levels are related to the rate of disease progression in cancer patients. Therefore, by detecting the expression level of CDK10, the disease progression of tumor patients can be detected early and provide important reference value for the treatment of tumor patients.

3. Combined treatment

In tumor treatment, combination therapy is very important. Studies have shown that the expression level of CDK10 can be used as an important target for combination therapy in tumor patients. Through combined therapy, different phenotypes of tumor cells can be targeted to intervene, thereby improving the therapeutic effect.

4. Targeted intervention

Targeted intervention against CDK10 can inhibit the spindle formation and mitosis of tumor cells by interfering with the activity of CDK10, thereby achieving the purpose of treating tumors. Currently, drugs targeting CDK10 are in clinical trials.

Protein Name: Cyclin Dependent Kinase 10

Functions: Cyclin-dependent kinase that phosphorylates the transcription factor ETS2 (in vitro) and positively controls its proteasomal degradation (in cells) (PubMed:24218572). Involved in the regulation of actin cytoskeleton organization through the phosphorylation of actin dynamics regulators such as PKN2. Is a negative regulator of ciliogenesis through phosphorylation of PKN2 and promotion of RhoA signaling (PubMed:27104747)

The "CDK10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets